HOME > TOP STORIES
TOP STORIES
-
REGULATORY MOF Panel Flags Japan’s High Drug Cost per Capita, Stays Pat on Cost-Effectiveness-Based Reimbursement, Copay Review
May 30, 2023
-
BUSINESS Jeremy Grossas to Head Up Merck Biopharma Japan
May 30, 2023
-
REGULATORY PM Advisors Make Irregular Call for Properly Rewarding Innovation to Boost Japan’s Drug Discovery Capabilities
May 29, 2023
-
REGULATORY Gene Therapy Luxturna Now in Line for Approval in June
May 29, 2023
-
BUSINESS Pfizer Japan Files RSV Vaccine for 60 Years of Age and Older
May 29, 2023
-
ORGANIZATION New JPMA Chief Renews Resolve for Drug Price Maintenance, Dynamic Policies
May 26, 2023
-
ORGANIZATION Mitsubishi Tanabe’s Ueno Elected as New JPMA President
May 26, 2023
-
REGULATORY Japan Approves Label Expansions for Ultomiris, Skyrizi, Vanflyta
May 26, 2023
-
BUSINESS Some 400 General Employees Likely Leaving Bayer under Redundancy Program
May 25, 2023
-
BUSINESS Lilly’s Omvoh Launch Set for June 21; BioMarin’s Palynziq Now Available
May 25, 2023
-
BUSINESS Novartis Japan Rolling Out New Operational Model Tailored to Local Needs: President
May 24, 2023
-
COMMENTARY Will Wegovy Lead the Way in Changing Picture of Obesity Treatment in Japan?
May 23, 2023
-
REGULATORY LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
May 23, 2023
-
REGULATORY Ophthalmic Mitomycin, OD Tablets for Takecab and Tarlige to Get Listing on May 24
May 23, 2023
-
REGULATORY MHLW Cancels Expert Panel Meeting on May 23, Report Delayed
May 23, 2023
-
BUSINESS Sawai and Towa Profits Tank 50% on Flat Sales in Japan: FY2022 Earnings
May 22, 2023
-
BUSINESS Astellas CEO Confident about Veozah Uptake, 500 Billion Yen Sales Potential
May 22, 2023
-
ORGANIZATION Industry, Academia Groups Applaud Govt’s New Biosimilar Goal, but Fret Pricing, Biosame Issues
May 19, 2023
-
BUSINESS Qol to Further Expand Espha's AG Biz, Eyes Biosame Territory: Exec
May 19, 2023
-
BUSINESS Lecanemab’s Social Value in Japan Simulated at 4.7 Million Yen per Patient/Year: Eisai
May 18, 2023
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
